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Abstract: Most ovarian cancer patients present with disseminated disease at the time of their diagnosis,
which is one of the main reasons for their poor prognosis. Metastasis is a multi-step process and a clear
understanding of the mechanism of regulation of these steps remains elusive. Productive reciprocal
interactions between the metastasizing ovarian cancer cells and the microenvironment of the metastatic
site or the tumor microenvironment play an important role in the successful establishment of metastasis.
Much progress has been made in the recent past in our understanding of such interactions and the
role of the cellular and acellular components of the microenvironment in establishing the metastatic
tumors. This review will outline the role of the microenvironmental components of the ovarian
cancer metastatic niche and their role in helping establish the metastatic tumors. Special emphasis
will be given to the mesothelial cells, which are the first cells encountered by the cancer cells at the
site of metastasis.
Keywords: ovarian cancer; microenvironment; metastasis; mesothelial cells; fibroblasts; adipocytes;
cross-talk; ECM
1. Introduction
Ovarian cancer is the most lethal gynecological cancer and the fifth leading cause of cancer-related
deaths among women in the USA [1]. It is estimated that in 2019, about 22,000 women will be diagnosed
with ovarian cancer and approximately 1400 will succumb to it in the USA [1]. Most patients are
diagnosed with metastatic disease and this causes the poor prognosis [2]. If detected early, the survival
rate is significantly higher. However, early stages of ovarian cancer do not show any noteworthy
symptoms and as the disease progress, the symptoms are vague and can be falsely attributed to other
conditions. In February 2018, the US preventive service task force recommended against a screening
program for ovarian cancer in women without any symptoms, if they do not carry any genetic
risk factors [1]. This makes it an even bigger challenge to detect ovarian cancer in the early stages.
Therefore, a majority of patients will be treated for metastatic disease. Since metastasis remains the least
understood aspect of cancer, it is imperative to focus on increasing our knowledge of the mechanisms
of regulation of its critical steps, in order to treat patients effectively. Moreover, it is important to
take into consideration the various stromal components of the tumor microenvironment, as well as
the microenvironment of the metastatic site, in the context of their role in inhibiting or facilitating
metastasis [3].
Epithelial ovarian cancer is the most common type, consisting of 90% of the cases [4]. It is further
classified into serous, mucinous, endometroid and clear cell carcinoma. Among them, high-grade
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serous ovarian carcinoma (HGSOC) is the most common and lethal subtype and accounts for about
70% of ovarian cancer-related deaths [4,5]. For a long time, the site of origin of epithelial ovarian cancer
was thought to be the ovarian surface epithelium. However, careful analysis of fallopian tube fimbria
from breast cancer type 1/2 (BRCA1/2) carriers undergoing bilateral salpingo-oophorectomy, identified
serous tubal intraepithelial carcinomas (STICs) present on the fallopian tube fimbria, as the precursors
of HGSOC [6]. Subsequently, several groups have established the fallopian tube as the precursor
of HGSOC. However, they can also be a site for metastasis in rare circumstances [7]. In most cases,
even though they originate as STICs in the fallopian tubes, they are disseminated to the neighboring
ovary, where the large primary tumor is formed.
Ovarian cancer predominantly undergoes a transcoelomic metastasis, where the cancer cells from
the primary tumor shed into the peritoneal cavity [8]. The flow of the peritoneal fluid then helps
spread them throughout the peritoneal cavity. At this stage, the cancer cells have to survive death due
to anoikis as well as immune surveillance. This is usually accomplished by aggregating into spheroids
and secreting extracellular matrix proteins to engage the cellular integrins. In addition, the cancer cells
have been reported to closely interact with microenvironment cells like cancer-associated fibroblasts
(CAFs), to help tide over the conditions while floating in the peritoneal fluid [9]. The cancer cells then
attach to the surface of the organs in the peritoneal cavity, most of which are covered by a layer of
mesothelium. Thereafter, they have to breach this protective covering and invade into the underlying
basement membrane (Figure 1). During this stage, they encounter a new microenvironment, and those
that successfully adapt to it eventually colonize the site of metastasis. The metastasizing cancer cells
are the most vulnerable at this stage, called metastatic colonization. Therefore, it is considered the
rate-limiting step of metastasis. Ovarian cancer can also metastasize through the hematogenous or
lymphatic routes, which are less predominant initially but may be responsible at late stages when the
disease spreads beyond the peritoneal cavity [8,10]. This review will focus on metastatic colonization,
taking into consideration the productive reciprocal interactions with the microenvironment, especially
the mesothelium that they encounter first, necessary for the successful establishment of the metastatic
tumors. The important secreted factors involved in the cross-talk are listed in Table 1.
Figure 1. The peritoneal microenvironment encountered by the metastasizing ovarian cancer cells
during the initial steps of metastatic colonization.
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2. Overview of the Mesothelium
The peritoneum is derived from mesoderm and is composed of two layers: Parietal and visceral
layers. The parietal layer lines the abdominal and pelvic walls while the visceral layer surrounds the
organs. The space between the parietal and visceral layer is called the peritoneal cavity. This cavity
normally contains a small amount of fluid composed of water, electrolytes, solutes, proteins and
cells. This fluid normally passes through the mesothelial layer to the lymphatic system. The origin of
this fluid is ultrafiltration from the capillaries, which is then drained into the lymphatic system [11].
Histologically, the peritoneal layers consist of a continuous, single layer of squamous cells called
mesothelial cells, with an underlying basement membrane. The mesothelial cells are tightly adherent
to each other by intercellular junctions and have microvilli on their surface [11]. The mesothelial cells
are polar with their apical surface facing the peritoneal cavity and their basal surface attached to the
basement membrane. The basement membrane consists of extracellular matrix proteins and embedded
fibroblasts. Underneath the basement membrane is the tissue stroma, containing cellular components
such as fibroblasts and macrophages and non-cellular components like collagen and glycoproteins [11].
The mesothelium not only forms a protective covering, it also serves as a semipermeable membrane.
The mesothelial cells help in the passage of intraperitoneal fluid to the lymphatic system and the
passage of other substances in and out of the peritoneal cavity [12]. They secrete phospholipids
and have a surface glycocalyx that helps generate a non-adhesive, protective surface and facilitate
intraperitoneal organ movements during peristalsis [13]. The mesothelium also has an interactive role
with its surrounding microenvironment during inflammation and cancer [13]. The mesothelial cells
recognize microbial pathogens that might invade the peritoneal cavity. This function is facilitated
by the expression of Toll-like receptors, nucleotide-binding oligomerization domain–like receptors,
retinoic acid-inducible gene-I-like receptors (RIG-I–like), and C-type lectin-like receptors on the
mesothelial cells [14]. The cytokines, growth factors, and extra cellular matrix (ECM) molecules
secreted by the mesothelial cells help in coordinating inflammatory responses and tissue repair [15].
Mesothelial cells secrete transforming growth factor (TGF), platelet-derived growth factor (PDGF),
fibroblast growth factor (FGF), hepatocyte growth factor (HGF), keratinocyte growth factor, and
epithelial growth factors (EGFs) [12,16]. These can promote autocrine as well as paracrine effects.
An interesting property of the mesothelium is their mechanism of repair, in case of wounding.
Mesothelial cells can migrate from the edges to cover the wound, but also can detach from opposing
surfaces and distant sites to settle on the wound surface to initiate repair [17]. In case of ovarian cancer,
the mesothelium serves as the first line of defense against the metastasizing cancer cells [18,19].
3. Priming the “Soil”
Stephen Paget was the first to suggest that metastatic homing of the cancer cells is not a random
process [20]. Interactions between cancer cells (the seed) and the metastatic site (the soil) regulate it.
Metastasis is successful only when the target metastatic site has the appropriate properties to accept
the message (molecular invitation) from the cancer cells [20,21]. In 1981, Hart et al. Suggested that
sarcoma from ovarian origin always metastasized to the abdominal organs whatever the rout of its
injection. When these ovarian cancer cells were injected intravenously, they were arrested in the lungs
and then slowly detached, recirculated, and were arrested in liver were they subsequently developed
into tumor nodules, which supported the soil and seed theory [22]. Similarly, ovarian cancer cells
homed in on the ovaries or omentum in mice [10,23]. In order to build an effective soil or premetastatic
niche (PMN), cancer cells secrete exosomes—extracellular vesicles containing DNA, messenger RNA
(mRNA), microRNA (miRNA), proteins, lipids and small metabolites etc. These exosomes have been
shown to carry the message to the PMNs and direct them to prepare a microenvironment suitable
for the future metastatic cells [24,25]. Since in ovarian cancer the primary tumor is present in the
peritoneal cavity, exosomes or secreted factors can potentially accumulate in relatively high localized
concentrations in the peritoneal fluid. As a result, these secreted factors may influence the peritoneal
microenvironment and prime them to accept metastasizing ovarian cancer cells. While several studies
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have been conducted on the priming of the metastatic niche in other cancers, future studies need to
focus on the role of priming of the peritoneal microenvironment by ovarian cancer [26–29].
4. Cancer Cells Induce Changes in the Mesothelium
4.1. Fibronectin Secretion
Mesothelial cells are considered the first line of defense against ovarian cancer metastatic
colonization in the peritoneum. Ovarian cancer cells attach more efficiently to the extracellular
matrix and fibroblast than to mesothelial cells [18]. However, during the early stages of cancer
metastasis, the induction of epithelial to mesenchymal transitions (EMT) causes a loss of the cell-cell
adherence because of the loss of E-cadherin. This is associated with increased expression of α5-integrin
through the epidermal growth factor receptor/focal adhesion kinase/mitogen-activated protein kinase
(EGFR/FAK/MAPK) pathway, which forms a heterodimer with β1-integrin and binds to fibronectin [30].
This is thought to facilitate adhesion of cancer cells to mesothelial cells as they secrete fibronectin [30].
Cleavage of the fibronectin into smaller fragments by cancer cell-derived metalloproteinase-2 (MMP2)
facilitated this adhesion [31]. Ovarian cancer cells secrete transforming growth factor beta (TGFβ)
which binds to the TGFβ receptors on the mesothelial cells, which then activate the Rac Family Small
GTPase 1/SMAD (RAC1/SMAD) signaling pathway. This leads to increased expression of fibronectin
and the activation of mesothelial mesenchymal transition, where mesothelial cells are transformed
into mesenchymal cells secreting fibronectin and providing a better adhesive substrate for the cancer
cells [31]. Blocking the interaction between α5β1-integrin and fibronectin was effective in treating
ovarian cancer metastasis in a prevention as well as intervention setting. The α5β1-integrin/fibronectin
interaction causes downstream activation of cMet, a receptor tyrosine kinase, independent of its ligand,
hepatocyte growth factor (HGF). Activation of cMet causes increased metastasis through the activation
of the focal adhesion kinase/src (FAK/Src) signaling pathway [32].
Since interfering with the interaction between the α5β1-integrin and fibronectin interaction was
found to be effective in reducing metastasis, a clinical trial was initiated using volociximab, a humanized
monoclonal antibody against the α5-integrin [33]. In 2011, Bell-McGuinn et al. published a phase II
clinical trial report on its role in the treatment of platinum-resistant ovarian cancer [34]. They found
that only 1 out of 13 patients had stable disease while using the drug even though it was well-tolerated
upon weekly administration. Further studies are required to optimize the dosage and test if it can be
effective in chemo-naive patients in combination with standard of care chemotherapy. Resveratrol,
a phytoalexin produced by certain plants when damaged by a pathogen, inhibits ovarian cancer cell
adhesion to mesothelial cells by decreasing α5β1-integrin levels and increasing levels of secreted
hyaluronic acid [35]. Similarly, resveratrol inhibits ovarian cancer tumor growth in combination with
cisplatin in mice [36]. In addition to the effects on α5β1-integrin and hyaluronic acid, resveratrol also
inhibits the growth of cancer cells through apoptosis [37] and downregulation of signal transducer
and activator of transcription 3 (STAT3) [38]. Extensive preclinical studies have been done with
resveratrol for its potential chemo-preventive properties in colorectal cancer and hepatic metastasis [39].
Investigations are ongoing to assess its pharmacokinetics and pharmacodynamics.
4.2. Tissue Plasminogen Activator Inhibitor Type 1 (PAI-1) Induction
TGFβ1 from the metastasizing ovarian cancer cells can induce the mesothelial cells to secrete
plasminogen activator inhibitor type 1 (PAI-1), which leads to an increased invasion of cancer cells
through the mesothelial cell layer. The secretion of PAI-1 is caused by activation of mitogen-activated
protein kinase (MAPK) in the mesothelial cells. The PAI-1 probably induces cancer cells invasion by
promoting cell–cell interactions [40]. Neutralizing antibodies against urokinase plasminogen activator
(uPA) or urokinase plasminogen activator receptor (uPAR) inhibited adhesion of the cancer cells to the
mesothelial layer, while blocking PAI-1 had the opposite effect [40]. However, uPA, uPAR, and PAI-1
all increased the invasion. Interestingly, the signaling between the cancer cells and the mesothelial
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cells appears to be reciprocal, since interactions with the mesothelial cells also induce increased TGFβ1
in cancer cells [41]. This is through a paracrine signaling mechanism.
Inhibition of PAI-1 leads to dissociation of PAI-1 and uPAR from α5-integrin and FAK, resulting in
the inhibition of phosphorylation of FAK and extracellular signal-regulated kinase (ERK). This causes
a decrease in proliferation and induction of G0/G1 cell cycle arrest, followed by apoptosis in both ovarian
cancer cells. Inhibition of FAK phosphorylation also leads to inhibition of peritoneal dissemination of
ovarian cancer cells [42]. Increased expression of PAI-1 is found in many ovarian cancer patient tumors
and it leads to poor prognosis, supporting the importance of PAI-1 in the disease progression [43].
However, increased plasminogen expression is a favorable prognostic marker in high-grade serous
ovarian cancer [44]. There is abundant evidence that uPA, its inhibitors PAI-1 and PAI-2, and its cells
surface receptor, uPAR, play a fundamental role in tumor invasion and metastasis and are of significant
prognostic significance for many tumor types [45]. Since many of these studies involve analysis of fully
formed tumors, it reflects the importance of PAI-1, uPA and uPAR in advanced metastasis, in addition
to their role in initial attachment and invasion through the mesothelium.
5. Mesothelial Clearance
The mesothelial cells naturally offer a non-adhesive, slippery surface. In order to establish
metastatic colonization, cancer cells need to attach to and then invade through the mesothelial cell
barrier in the peritoneum in order to establish metastasis [18,46]. Biopsies from advanced epithelial
ovarian cancer attached to peritoneum indicate that the mesothelial cell layer in them is not continuous,
and the mesothelial cells have a different morphology compared to the normal mesothelium [47].
Niedbala et al. developed an in vitro model to study the interactions between mesothelial and cancer
cells [46]. Ovarian cancer cells disrupt the mesothelial cell–cell adhesions, which results in retraction
of the mesothelial cells away from each other. This leads to the exposure of the extracellular matrix,
to which the cancer cell can attach more efficiently [46]. Iwanicki et al. studied such mesothelial
clearance using live imaging in an in vitro model [19]. Their study demonstrated that cancer cells
disrupt the mesothelial cell layer using a myosin retraction force, which depended on α5-integrin and
talin. Mesothelial cells in direct contact with the ovarian cancer cells migrate for longer distances
than mesothelial cells that did not contact the cancer cells. Blocking α5-integrin using a neutralizing
antibody decreases the mesothelial clearance, but blocking of αV- or α2-integrin, or CD44 did not have
a similar effect. This suggests that cancer cell attachment to the mesothelial cell-secreted fibronectin,
specifically through the α5-integrin, is essential for mesothelial cell clearance. The cancer cells attach
to the mesothelial cells using the α5β1-integrin–fibronectin interaction, causing the activation of talin I,
which is associated with the α5β1 integrin, and subsequently activates myosin-mediated contraction.
This leads to detachment of fibronectin from the surface of the mesothelial cell layer and mesothelial
clearance [19]. The same group later demonstrated that EMT correlates with the ability of the ovarian
cancer cells to clear the mesothelial layer [48]. They found that cancer cell spheroids that attached
to mesothelial cells contain a heterogenous population of cells with different abilities to clear the
mesothelial layer. The cells with greater ability to clear the mesothelial layer exhibit high levels of
mesenchymal markers. Clearance competence correlates with TGFβ-dependent induction of EMT via
SMADs [48]. Exosomal miR-21 and miR-29a increase mesothelial clearance and are associated with
poor survival rates [49]. Mesothelial cell clearance may also be facilitated by the migration induced
in them by HGF and EGFR ligands present in malignant ascites [50]. These growth factors mediate
migration of mesothelial cells via activation of cMet, which signals through MAPK and AKT to induce
migration in the mesothelial cells.
6. Mesothelial Mesenchymal Transition (MMT)
Mesothelial cells may acquire fibroblast-like characteristics under certain conditions like
inflammation or activation of repair response, in cases of peritoneal dialysis [51]. The newly formed
fibroblast-like cells are able to synthesize inflammatory mediators, angiogenic factors, and altered extra
Cancers 2019, 11, 1608 6 of 17
cellular matrix (ECM) [52]. Cancer associated fibroblasts (CAFs) are a prominent cell population in
tumors and promote most stages of cancer growth and progression. CAFs can originate by the activation
of resident fibroblasts, recruitment of precursor cells derived from the bone marrow, mesenchymal stem
cells or from endothelial cells [53–55]. However, another potential source of CAFs can be mesothelial
cells undergoing MMT, similar to what happens in peritoneal dialysis patients. MMT is dependent
on the TGFβ/SMAD pathway [56]. Histological observations of the peritoneal ovarian metastatic
nodules identified spindle-shaped cells in the sub-mesothelial regions [54]. Immunostaining revealed
that these spindle cells express both mesothelial markers and CAF markers like α-smooth muscle
actin (αSMA). These results were verified using specific cytokeratin expression profiles in cancer cells
and normal mesothelial cells. Culturing mesothelial cells with conditioned medium from ovarian
cancer cells causes the acquisition of a spindle-like morphology, similar to mesothelial cells treated
with TGFβ and IL1β. It also causes the upregulation of MMT markers like fibronectin, vascular
endothelial growth factor (VEGF) and TGF β1 in mesothelial cells [54]. Malignant ascites is abundant
in cytokines [56], chemokines [57], exosomes [58,59], and growth factors [50]. The presence of these
factors may contribute towards increased tumor attachment, invasiveness and colonization [60,61].
In addition, they could possibly induce MMT in a manner similar to that observed in peritoneal
dialysis patients [62,63]. In peritoneal dialysis patients, HGF is thought to inhibit the effect of glucose
in enhancing the MMT [64]. However, in ovarian cancer patients, HGF can potentially induce
the MMT [65].
TGFβ1 from ovarian cancer cells can also induce MMT by increasing RhoA activity. The Rho
kinase (ROCK) inhibitor, Y-27632, decreases TGFβ1-induced MMT, confirming this mechanism [66–68].
Statins block the HMG reductase enzyme, which subsequently decrease isoprenoids, which are required
by Rho GTPases [69]. Using statins decreased MMT in peritoneal dialysis patients [70]. Retrospective
analysis of patients with epithelial ovarian cancer showed that using statins increased the progression
free survival, after the cytoreductive therapy, by about eight months, and overall survival by about
16 months [71]. However, the improved survival may be related to inhibition of RhoA-mediated
increases in invasiveness of cancer cells and not just inhibition of MMT [72]. Xie et al. conducted
a meta-analysis on the effect of statins in improving the survival in patients with gynecological cancers.
They did not find randomized controlled trials, however, they found 10 retrospective cohorts and one
case control study. Based on these, they concluded that statins may improve the overall survival and
progression free survival [73]. Astragaloside IV is a traditional Chinese herbal medication extracted
from Astragalus membranaceus. It showed an inhibitory effect on the TGFβ1-induced MMT [74].
Astragaloside IV induces miR-134 expression, leading to a decrease in expression of cyclic adenosine
monophosphate (cAMP) responsive element binding protein 1 (CREB1), which is a proto-oncogene
regulating cancer progression, and promotes EMT, in colorectal cancer [75].
Dexamethasone inhibits TGFβ1-induced phosphorylation of MAPK and p38 MAPK.
This inhibition is independent of SMADs. Interestingly, Dexamethasone reversed the TGFβ1-mediated
MMT in peritoneal mesothelial cells or induced mesenchymal to epithelial transition [76].
Glucocorticoids may be used in ovarian cancer patients either to reduce nausea from the
chemotherapy or to prevent the paclitaxel-induced hypersensitivity [77,78]. However, administration
of glucocorticoids in ovarian cancer patients may increase the level of antiapoptotic genes,
which subsequently decrease the effectiveness of chemotherapy in ovarian cancer patients [79].
Tamoxifen, a selective estrogen receptor modulator (SERM), is thought to decrease the TGFβ1-induced
MMT, not reversing it, in peritoneal dialysis-derived mesothelial cells [80]. Paleari et al. conducted
a meta-analysis including 53 randomized clinical trials with 2490 patients, in order to study the effect
of endocrine therapy with tamoxifen and aromatase inhibitors. They found that tamoxifen showed the
highest summary clinical benefit rate compared to the other therapies. The endocrine therapy carries
lower risk compared to other treatments or placebo [81].
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7. Metastatic Colonization
Once the metastasizing ovarian cancer cells have breached the mesothelium, they initiate the
process of metastatic colonization. This involves extensive, productive cross-talk between the cancer
cells and their new microenvironment [82]. Such interactions can trigger adaptive responses in the
cancer cells, which enable them to adjust to the new microenvironmental factors and start establishing
the metastatic tumor. Such adaptive responses include changes in gene expression, to take advantage
of, or adjust to the factors present in the new microenvironment. The interactions with the omental
microenvironment trigger changes in microRNAs, DNA methylation and transcription factors in
the ovarian cancer cells [83,84]. The initial interactions with the mesothelial cells cause a decreased
expression of the tumor suppressor microRNA, miR-193b [83]. This promotes metastatic colonization
by increasing invasiveness and proliferation of the cancer cells. Overexpression of miR-193b causes
a significant decrease in metastasis in mouse xenografts, while stable inhibition leads to an increase in
metastasis [83]. microRNAs act through the translational inhibition of their targets. One of the key
targets of miR-193b is uPA. Downregulation of miR-193b in the metastasizing ovarian cancer cells
through the interactions with the mesothelium causes the concomitant increase in expression of its
direct target uPA. Functional rescue experiments implicate that this increase in uPA is responsible for
the increased invasiveness and proliferation of the metastasizing ovarian cancer cells [83]. Interestingly,
the downregulation of miR-193b is induced by promoter hypermethylation through DNA methyl
transferase 1 (DNMT1).
Transcription factors are important regulators of gene expression, and the initial interactions
with the mesothelium can trigger deregulation of transcription factors, because of the signals from
the new microenvironment. One of the key capabilities for successful colonization is the ability to
invade into the tissue parenchyma of the metastatic organ. Several members of the erythroblast
transformation-specific (ETS) family of transcription factors have the ability to increase motility of
the cancer cells [85,86]. Among the oncogenic members of the ETS family, ETS 1 is the most induced
in the metastasizing ovarian cancer cells [84]. This is triggered by the direct interaction with the
mesothelium, which activated MAPK signaling in the cancer cells. MAPK can phosphorylate and
activate ETS1, which can then transcribe itself and other targets. Among the ETS1-regulated genes
in metastasizing ovarian cancer cells, protein tyrosine kinase 2 (PTK2) plays a key role in promoting
metastasis [84]. PTK2 codes for FAK and activated ETS1 causes an increased expression of FAK.
Interestingly, the ligand-independent activation of cMET by α5-integrin causes phosphorylation and
activation of FAK during metastasis. This points toward a synergistic effect of extracellular signals for
the metastatic microenvironment on both increasing the expression and activation of FAK, implicating
it as a key factor in driving metastatic colonization in ovarian cancer.
8. Fibroblasts in Metastatic Colonization
Fibroblasts are a major cellular component and source of ECM in tumor microenvironment
(TME) [87]. Depending on their site of origin and host stromal tissue type, fibroblasts display
heterogeneous phenotypes by activating different transcriptional programs controlled by epigenetic
modifications and paracrine signaling. It is interesting to see contradicting anti-tumorigenic function
of normal fibroblast and pro-tumorigenic responses of CAFs [88–90]. Normal fibroblasts play
an essential role in organizing ECM by altering expression and activities of adhesion molecules,
other cellular components and fine-tuning the balance of various proteolytic enzymes and tissue
inhibitors. Maintaining normal stromal architecture and configuring normal epithelial phenotype
by fibroblasts is an important defense against metastatic colonization. Normal fibroblasts also cause
“neighbor suppression” by inhibiting the growth of adjacent abnormal or transformed cells [91].
Contact-independent tumor suppression is accomplished via different cytokines and chemokines such
as tumor necrosis factor-alpha (TNF-alpha), IL-6, and TGF-beta released by fibroblasts. Fibroblasts are
also a key constituent of the basement membrane of the omentum and the peritoneum [82]. They secret
the ECM that form the basement membrane, and multiple other factors that are trapped in the ECM.
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These fibroblasts are among the first cells encountered by the metastasizing ovarian cancer cells.
Interactions with such resident normal fibroblasts can induce changes in microRNAs in the ovarian
cancer cells that can help them adapt to the new microenvironment (unpublished data). At the same
time, the cancer cells have the ability to reprogram these normal fibroblasts into CAF by altering the
expression of a set of microRNAs in them [92]. The cancer cell-induced decrease in the expression of
miR-214 and miR-31 and an increase in the expression of mi-R155 converts normal fibroblasts into CAFs.
Interestingly, CAFs could be converted back into normal fibroblasts by the combined over-expression
of miR-214 and miR-31 and the inhibition of miR-155. The CAFs then promote cancer cells invasion
and proliferation by secreting several chemokines and cytokines including C-C motif chemokine ligand
5 (CCL5), which is a direct target of miR-214. Inhibition of CCL5 in nude mice co-injected with ovarian
cancer cells and CAFs significantly decreased the ability of the CAFs to promote tumor growth and
metastasis [92]. Recent proteomics studies have revealed that the methyltransferase nicotinamide
N-methyltransferase can also help reprogram CAFs into an activated state that supports metastasis [93].
The ability to reprogram the resident normal fibroblasts is key to successfully establishing the
metastasis. Once activated, the CAFs secrete many factors that remodel the ECM, promote cancer cell
growth and invasion, trigger angiogenesis, and have immunomodulatory functions, together promoting
metastasis [87]. Other cell types, such as fibrocytes, epithelial cells (through EMT), mesenchymal stem
cells, pericytes, adipocytes, and endothelial progenitor cells can differentiate and provide the source of
CAFs as well [94]. This switch of normal stroma into CAF-containing TME is one of the fundamental
steps promoting tumor development. In addition to secreting growth factors including hepatocyte
growth factor (HGF), stromal-derived factor-1 (SDF-1) and fibroblast growth factor (FGF), that directly
affect cell motility, CAFs are the source of ECM-degrading proteases such as the MMPs. Cancer cell
invasion through the basement membrane is a complex process, involving stepwise adhesion and
proteolysis. However, basement membrane invasion can also be achieved by CAFs pulling and
stretching their plasma membranes [95,96]. This creates gaps in the basement membrane that allow
the cancer cells to invade even without proteolytic MMP activity [95]. CAFs also facilitate stromal
dissemination of cancer cells that have not completely undergone EMT, by paving the way and forming
ECM tracks [97,98]. The CAF-directed cancer invasion through stroma can utilize matrix-degrading
proteases at the surface of the leader fibroblasts. At the metastatic site, depletion of all four members
of tissue inhibitor of metalloproteinases (TIMP) causes activation of CAFs and secretion of exosomes
containing MMPs, miR-45 and other ECM proteins. Paracrine signaling via chemokines such as IL-6,
IL-11 produced by CAFs activates the janus kinase2/signal transducer and activator of transcription
3 (JAK2/STAT3) pathway, which enhances the ability of cancer cells to undergo EMT and facilitates
growth and metastasis to peritoneum [99,100]. C-X-C motif chemokine 12 (CXCL12) secreted by CAFs
can also induce EMT in oral squamous cell carcinoma and breast cancer models [101,102].
While this review focusses on metastatic colonization, the CAFs can also play a role in the
dissemination of cancer cells from the primary tumor to the site of peritoneal metastasis. The exfoliated
ovarian cancer cells floating in the ascites as spheroids contain CAFs as well as activated mesothelial
cells, which contribute to the development of ascitic microenvironment, assist cancer cell survival
and subsequent colonization of the metastatic site. These spheroids represent the invasive and
chemoresistant cellular population. They also contain various acellular elements like cytokines and
ECMs that contribute to the development of the ascitic microenvironment, assist cancer cell survival
and subsequent colonization of the metastatic site [9,103,104]. Ascitic tumor cells in HGSOC are
characterized by high levels of α5-integrin expression, which tend to form heterotypic spheroids with
fibroblasts. There is a reciprocal cooperation between the cancer cells and fibroblasts, where ovarian
cancer cells with high α5-integrin expression are selectively recruited by CAFs to form the unique
heterotypic spheroids. Similarly, activated CAFs secrete EGF that supports survival of the cancer cells,
direct their peritoneal and transperitoneal adhesion and invasion and finally, constitute the tumor
stroma in newly formed metastases [9].
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Cancer cells can prime and recruit stromal components such as fibroblasts at the distant metastatic
site (the PMN) to secrete ECM proteins such as fibronectin. Fibronectin, an extracellular matrix
glycoprotein involved in numerous cellular processes including embryonic cell migration and vascular
development, also appears to be an important component of PMN. In pancreatic ductal adenocarcinoma
(PDAC) metastasizing to liver, resident hepatic stellate cells can be activated into periostin-secreting
myofibroblasts through granulin secreted by tumor-associated macrophages (TAMs) [105]. At the
metastatic niche, fibroblast-specific protein 1 (FSP1)-positive cells have also been found to enhance
cancer cell metastasis via vascular endothelial growth factor A (VEGFA) secretion, and depletion of
these cells significantly reduces the metastatic colonization, while primary tumor growth remains
unaffected [106]. CAFs also promote neoangiogenesis in metastatic TME by modulating connective
tissue growth and micro-vessel density [91]. CAFs in the omental metastasis can also play an important
role in the metabolic switch happening in the cancer cells, as a result of depletion of available fatty
acids, as the tumor progresses [107]. CAFs caused the activation of phosphoglucomutase 1 in the
cancer cells, enabling them to utilize glycogen as an energy source instead. Overall, CAFs appear to be
important contributors towards the initial steps of ovarian cancer metastatic colonization, as well as in
advanced metastasis.
9. Role of Adipocytes in Metastatic Colonization
An important and abundant cellular component of the omentum is the adipocyte.
Omental adipocytes secrete adipokines such as IL-8, IL-6, monocyte chemoattractant protein-1
and adiponectin, which promote homing of metastasizing ovarian cancer cells to omentum [108].
Cancer cells affect metabolism in adipocytes by inducing hydrolysis of triglycerides, stored in adipocyte
lipid droplets, into free fatty acids and glycerol [108]. The glycerol can potentially be fed into the
glycolytic pathway and facilitate metabolic adaptation of the tumor in the new metastatic niche.
The adipocytes also induce the expression of FABP4, a fatty acid transporter, in the cancer cells.
Interestingly, FABP4 is also present in endothelial cells, where it appears to regulate cell proliferation
and angiogenesis. The lipid transfer from adipocytes induces β-oxidation in tumor cells and enhances
their proliferation in vitro [108]. The adipocytes also induce the expression of CD36 in the ovarian
cancer cells that help uptake of the fatty acids and the eventual utilization to promote metastatic
growth [109]. In addition, adipocytes induce calcium-dependent activation salt-inducible kinase 2
in the ovarian cancer cells, activating the phosphoinositide 3-kinase/AKT (PI3K/AKT) pathway and
phosphorylating acetyl-CoA carboxylase, promoting metastasis [110]. Essentially, it appears that
cancer cells force adipocytes to ‘give up’ their lipids. Through paracrine secretions and the abundance
of readily transferable lipids, adipocytes create a microenvironment that alters tumor metabolism and
supports phenotypes that are more aggressive. This process eventually leads to the transformation
of omentum from a fat pad into a solid tumor mass with few remaining adipocytes, a process often
referred to as ‘omental caking’. Interestingly, targeting the adipocytes with a DNA methyltransferase
(DNMT) inhibitor can affect their ability to promote cancer cell migration and proliferation [111].
Adipocytes also interact with peritoneal macrophages and facilitate their activation to
a tumor-associated phenotype (tumor-associated macrophage). It has been demonstrated that
adipocyte-supplied poly-unsaturated fatty acids (PUFAs) serve as ligands for transcription factor
peroxisome proliferator-activated receptor β/δ (PPARβ/δ) in macrophages [112]. This fatty acid
accumulation leads to transcriptional deregulation and pro-tumorigenic phenotype in peritoneal
macrophages. These macrophages contribute to the formation of new “milky spots” around the homed
tumor cells in omentum [113,114]. Once adhered, the tumor cells deplete the adipocytes and induce
hypoxia, which leads to increased angiogenesis, and advances metastatic progression even when fat
stores are depleted [115]. Omental fat cells also activate pro-survival pathways, p38 and STAT3, in the
ovarian cancer cells, indicating the potential importance of an adipocyte-rich environment for homing
and growth of tumor cells in the omentum.
Secrete adipokines are shown in Table 1 together with other secreted factors.
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Table 1. Secreted factors involved in reciprocal interactions between metastasizing ovarian cancer cells
and the microenvironment.
S.No Secreted Factors Sources References
1 Transforming growth factor-β (TGF-β) Mesothelial cells [12,16]
2 Transforming growth factor-β (TGF-β) Cancer cells [71]
3 Platelet-derived growth factor (PDGF) Mesothelial cells [12,16]
4 Fibroblast growth factor (FGF) Mesothelial cells [12,16]
5 Hepatocyte growth factor (HGF) Mesothelial cells [12,16]
6 Keratinocyte growth factor (KGF) Mesothelial cells [12,16]
7 Epithelial growth factors (EGFs) Mesothelial cells [12,16]
8 Cytokines like IL6, stroma derived factor 1(SDF1), leucine leucine 37 (LL 37) Cancer cells [27,28]
9 Fibronectin Mesothelial cells [71]
10 Matrix metalloprotease 9 (MMP 9) Fibroblasts [30,97]
11 Plasminogen activator inhibitor type 1(PAI-1) Mesothelial cells [43]
12 Urokinase plasminogen activator (uPA) [53]
13
Cytokines (angiogenin, angiopoietin-2, GRO,
ICAM-1, IL-6, IL-6R, IL-8, IL-10, leptin, MCP-1,
MIF NAP-2, osteprotegerin (OPG), RANTES,
TIMP-2 and UPAR were elevated in most
malignant ascites)
Malignant ascites [53]
14 Chemokines (CCL2, -3, -4, -5, -8, and -22) Malignant ascites [60]
15 Chemokines (IL-6, IL-11) Cancer associatedfibroblasts [101]
16 Exosomes/Membrane vesicles/microvesicles Malignant ascites [61,62]
17 Fatty acid binding protein 4 (FABP4) Adipocytes [110]
18 Adipokines (IL-8, IL-6), monocytechemoattractant protein-1 and adiponectin Adipocytes [110]
10. Conclusions
In conclusion, the process of metastasis involves productive interactions with both the cellular and
acellular microenvironmental components. The use of effective three-dimensional (3D) culture models
in the recent past have improved our understanding of the mechanisms of such interactions and the
roles that they play in metastasis. The reciprocal interactions between the metastasizing ovarian cancer
cells and the microenvironment of the metastatic site may be initiated very early in the form of secreted
factors produced by the primary tumor to prime the microenvironment to develop into a PMN that
produces factors that induce homing of the metastasizing cells and the subsequent establishment of the
disseminated tumor (Figure 2). At the metastatic site, the cross-talk can be mediated through paracrine
and juxtacrine signaling that helps establish the tumor and reprogram the microenvironment into
an ‘activated’ tumor promoting stroma. This activated stroma continues to play an important role in
the progression of metastasis. However, much remains to be learned and further studies are needed
to fully understand the reciprocal interactions that are essential for successful metastasis. As our
knowledge in this area increases, it will help identify novel therapeutic targets that are potentially
effective in treating ovarian cancer metastasis. Since a majority of ovarian cancer patients already have
metastatic disease at the time of diagnosis, such novel therapies may help improve their outcome.
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Figure 2. An overview of ovarian cancer metastatic colonization. Starting with priming of the
metastatic niche by secreted factors, including exosomes, from the primary tumor (1), followed by
mesothelial clearance (2) and reciprocal interactions between cancer cells and the microenvironment.
This eventually results in metastatic colonization (4) and reprogramming of the stroma into an ‘activated’
tumor-promoting stroma (5).
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